NCT04118699View on ClinicalTrials.gov

Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 25, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

January 31, 2022

Conditions
Chronic Intestinal Pseudo-obstruction
Interventions
DRUG

Rifaximin oral tablet

Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks

DRUG

Placebo oral tablet

Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks

Trial Locations (1)

236-0004

Yokohama city university, Yokohama

Sponsors
All Listed Sponsors
collaborator

ASKA Pharmaceutical Co., Ltd.

INDUSTRY

lead

Yokohama City University

OTHER